IO Biotech (IOBT) Price & Analysis

Compare

387 Followers

IOBT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $2.48

Previous CloseN/A

Volume57.25K

Average Volume (3M)458.79K

Market Cap

$69.17M

Enterprise Value$36.49M

Total Cash (Recent Filing)$37.09M

Total Debt (Recent Filing)$1.76M

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Aug 08, 2025

EPS Estimate

-0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding65,880,910

10 Day Avg. Volume567,505

30 Day Avg. Volume458,787

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.53

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-170.50

Enterprise Value/Ebitda-0.38

Forecast

1Y Price Target

$9.00

Price Target Upside587.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe trial demonstrated a median progression-free survival of 19.4 months in the combination treatment, which is an impressive 8+ month benefit compared to 11.0 months with pembrolizumab alone.

Financial HealthThe company ended 2024 with $60 million in cash and equivalents, which is projected to be sufficient to fund operations into 2026.

Regulatory ProgressCylembio's approval would position it as a first-in-class therapeutic cancer vaccine for patients with advanced melanoma.

Bears Say

Clinical Trial UncertaintyThe trial narrowly missed the primary endpoint of progression-free survival with a p-value of 0.056 versus the threshold of 0.045.

Commercial CompetitionThe company faces risks such as safety signals in clinical programs, lower-than-expected efficacy, and greater-than-expected commercial competition.

Market RisksThere is a risk of delisting if the company's shares go under $1.

IO Biotech News

IO Biotech says statistical significant missed on primary endpoint for Cylembio

IO Biotech (IOBT) announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic...

3d ago

IOBT

IO Biotech files to sell 4.22M shares of common stock for holders

17:24 EDT IO Biotech (IOBT) files to sell 4.22M shares of common stock for holders Published first on...

20d ago

IOBT

Promising Phase 3 Results and Strategic FDA Engagement Bolster Buy Rating for IO Biotech

IO Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

2d ago

IOBT

IO Biotech Reveals Phase 3 Trial Results for Cylembio

IO Biotech ( ($IOBT) ) has shared an announcement. On August 11, 2025, IO Biotech announced the topline...

3d ago

IOBT

IO Biotech Issues Tranche B Warrant to EIB

The latest update is out from IO Biotech ( ($IOBT) ). On June 24, 2025, IO Biotech issued...

2M ago

IOBT

IO Biotech Amends CEO Service Agreement

IO Biotech ( ($IOBT) ) has issued an announcement. On June 19, 2025, IO Biotech ApS, a subsidiary...

2M ago

IOBT

IO Biotech Elects New Director at Annual Meeting

The latest update is out from IO Biotech ( ($IOBT) ). On June 5, 2025, IO Biotech, Inc....

2M ago

IOBT

IO Biotech Regains Nasdaq Compliance with Stock Price

IO Biotech ( ($IOBT) ) has issued an update. IO Biotech, Inc. faced a compliance issue with Nasdaq’s...

2M ago

IOBT

IO Biotech files to sell 5.62M shares of common stock for holders

The company will not receive any of the proceeds from the sale of its common stock by the...

3M ago

IOBT

IO Biotech Advances Cancer Vaccine Trials in Q1 2025

Io Biotech, Inc. ( ($IOBT) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

IOBT

IO Biotech: Promising Future with Strong Clinical Progress and Financial Backing

TD Cowen analyst Yaron Werber has maintained their bullish stance on IOBT stock, giving a Buy rating today....

3M ago

IOBT

Optimistic Outlook on IO Biotech: Promising Cancer Treatment Developments and Strategic Growth Moves

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), boosting...

3M ago

IOBT

IO Biotech price target raised to $14 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a...

3M ago

IOBT

IO Biotech reports Q1 EPS (34c) vs (30c) last year

“IO Biotech (IOBT) continues to make meaningful progress developing novel cancer therapies that are designed to address significant...

3M ago

IOBT

IOBT FAQ

What was IO Biotech’s price range in the past 12 months?

IO Biotech lowest stock price was $0.66 and its highest was $2.48 in the past 12 months.

What is IO Biotech’s market cap?

IO Biotech’s market cap is $69.17M.

When is IO Biotech’s upcoming earnings report date?

IO Biotech’s upcoming earnings report date is Aug 08, 2025 which is 6 days ago.

How were IO Biotech’s earnings last quarter?

IO Biotech released its earnings results on May 14, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.373 by $0.033.

Is IO Biotech overvalued?

According to Wall Street analysts IO Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IO Biotech pay dividends?

IO Biotech does not currently pay dividends.

What is IO Biotech’s EPS estimate?

IO Biotech’s EPS estimate is -0.36.

How many shares outstanding does IO Biotech have?

IO Biotech has 65,880,910 shares outstanding.

What happened to IO Biotech’s price movement after its last earnings report?

IO Biotech reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.373. Following the earnings report the stock price went down -4.233%.

Which hedge fund is a major shareholder of IO Biotech?

Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at 0.

IO Biotech Stock Smart Score

Outperform

Fundamentals

Return on Equity

-138.78%

Trailing 12-Months

Asset Growth

-64.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IO Biotech

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech (IOBT) Earnings & Revenues

Historic Earnings Reports

IOBT Stock 12 Month Forecast

Average Price Target

$9.00

▲(587.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3,7,11,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.22,3.126153846153846,4.032307692307692,4.938461538461539,5.844615384615384,6.750769230769231,7.656923076923077,8.563076923076922,9.46923076923077,10.375384615384615,11.281538461538462,12.187692307692307,13.093846153846153,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.22,2.741538461538462,3.263076923076923,3.7846153846153845,4.306153846153846,4.827692307692308,5.349230769230769,5.8707692307692305,6.392307692307693,6.913846153846153,7.435384615384615,7.956923076923077,8.478461538461538,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.22,2.356923076923077,2.493846153846154,2.6307692307692307,2.767692307692308,2.9046153846153846,3.0415384615384617,3.1784615384615384,3.315384615384615,3.4523076923076923,3.5892307692307694,3.726153846153846,3.863076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.87,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >